Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Tend to second-line therapy in lung cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Apr 2015

Kobayashi Haruki, Takahashi Toshiaki

Abstract excerpt

Second-line chemotherapy has been established for non-small-cell lung cancer(NSCLC)and sensitive relapsed small cell lung cancer(SCLC).Molecular targeted drugs, such as EGFR- and ALK-inhibitors, have improved survival outcome remarkably in patients with NSCLC harboring EGFR mutations or EML4-ALK fusion proteins.In addition, targeted drugs that may overcome T790M-mediated EGFR-TKI resistance have been developed,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Recurrence
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Carcinoma, Non-Small-Cell Lung

Share to Carcinoma, Small Cell

Share to ErbB Receptors

Share to EML4 gene

Source

Identifiers

PMID: 25963689

Genes

EGFR
ALK
EML4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Tend to second-line therapy in lung cancer].PMID 25963689Read ↗

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read ↗

[Advances in research on primary resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients].Semantic proximity Read ↗

[Research progress of the resistance mechanism of non-small cell lung cancer to EGFR-TKIs].Semantic proximity Read ↗

[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].Semantic proximity Read ↗

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read ↗

[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].Semantic proximity Read ↗

[Resistances to targeted therapies and strategy for following therapeutic lines in metastatic NSCLC].Semantic proximity Read ↗

[Acquired resistance mechanisms to EGFR-TKIs in EGFR mutated lung cancers].Semantic proximity Read ↗

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.Semantic proximity Read ↗

[Development of molecular targeted therapies in lung cancers].Semantic proximity Read ↗

[Overcoming resistance to EGFR-TKI in lung cancer].Semantic proximity Read ↗

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.